Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients treated with ICT prior to definitive (chemo)radiotherapy ((C)RT) according to multidisciplinary team (MDT) conferences based decisions. Further to investigate the use of pHPV measurements and other relevant markers for prediction of response and survival after ICT prior to definitive (C)RT.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histological verified squamous cell carcinoma of the anus

• Treatment with ICT prior to definitive CRT or RT due to locally advanced disease or

• Patients with synchronous metastatic disease treated with ICT with the purpose of definitive CRT (potentially in combination with organ directed therapy (surgery, RFA, SBRT) for the metastatic sites)

• Age ≥ 18 years

• Written and orally informed consent

Locations
Other Locations
Denmark
Department of Oncology, Aarhus University Hospital
RECRUITING
Aarhus
Department of Oncology Herlev and Gentofte Hospital
NOT_YET_RECRUITING
Herlev
Department of Oncology, Vejle hospital, University Hospital of Southern Denmark
NOT_YET_RECRUITING
Vejle
Contact Information
Primary
Karen L Wind, MD
karen.lycke.wind@auh.rm.dk
20614431
Time Frame
Start Date: 2022-01-01
Estimated Completion Date: 2025-12
Participants
Target number of participants: 60
Treatments
Locally advanced or synchronous metastatic anal cancer treated with induction chemotherapy
Patients with newly diagnosed anal cancer who by standard of care are eligible for induction chemotherapy prior to definitive CRT or radiotherapy alone (RT) will be screened according to inclusion- and exclusion criteria. Patients eligible for induction chemotherapy will be patients with locally advanced or synchronous metastatic anal cancer.
Related Therapeutic Areas
Sponsors
Leads: Aarhus University Hospital

This content was sourced from clinicaltrials.gov